Text Size

Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: An in vivo toxicity assay

Liang H., Baudouin C., Faure M.-O., Lambert G., Brignole-Baudouin F.

  • 2009
  • Molecular Vision
View publication
  • Therapeutic Area


  • Technology


  • Categories

    Preclinical development

  • Affiliations

    Paris Descartes University, Faculty of Biological and Pharmacological Sciences, Department of Toxicology, Paris, France; INSERM, Institut de la Vision, Department of Therapeutics, 17 rue Moreau, 75012 Paris, France; UPMC University Paris, Institut de la Vision, Paris, France; Quinze-Vingts National Hospital of Ophtalmology, Department of Ophthalmology, Paris, France; Quinze-Vingts National Hospital of Ophtalmology, Department of Biology, Paris, France; Ambroise Paré Hospital, APHP, Versailles Saint-Quentin en Yvelines University, Paris, France; Novagali Pharma SA, Evry, France

Related Publications

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Esaki Y., Katsuta O., Kamio H., Noto T., Mano H., Iwamura R., Yoneda K., Odani-Kawabata N., Morishima K., Shams N.K.

In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models

Liang H., Baudouin C., Daull P., Garrigue J.-S., Buggage R., Brignole-Baudouin F.

A comparative study of a preservative-free latanoprost cationic emulsion (catioprost) and a BAK-preserved latanoprost solution in animal models

Daull P., Buggage R., Lambert G., Faure M.-O., Serle J., Wang R.-F., Garrigue J.-S.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022